Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of CPI-0610 in Hematological Malignancies and Myeloproliferative Neoplasms
NCT02158858Phase 2Completed
- Sponsor
- Constellation Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of pelabresib in myelofibrosis (MF), essential thrombocythemia (ET), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), sponsored by Constellation Pharmaceuticals. Started Jul 2014; status: completed.
02
Drugs
pelabresib
03
Conditions
myelofibrosis (MF)essential thrombocythemia (ET)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02158858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158858.